SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of cumulative effect adjustment and the impact on current period financial statements of adopting Topic 606

	Three months ended December 31, 2018 (unaudited)
	prior U.S. GAAP			Topic 606 impact			as reported
Statement of Operations
Revenues
Product	$	704,972		$	(383,097	)	$	321,875
Service	$	570,075			(7,628	)		562,447
Total revenues		1,275,047			(390,725	)		884,322
Cost of revenues		156,818			(3,333	)		153,485
Loss from operations		(2,808,768	)		(387,391	)		(3,196,159	)
Assets
Prepaids and other current assets	$	625,490		$	(3,333	)	$	622,157
Liabilities and stockholder's equity
Deferred Revenue	$	1,484,963		$	(109,467	)	$	1,375,496
Accumulated Deficit		(251,001,046	)		(106,134	)		(251,107,180	)

Schedule of operations and timing of revenue recognition

	Three Month Period Ended:
	December 31, 2018		December 31, 2017
Research and development services (over-time)	$	473,178	$	221,863
Product and authentication services (point-in-time):
Supply chain		250,098		69,852
Asset marking		161,046		248,024
Large scale DNA production		-		107,938
Total	$	884,322	$	647,677

Schedule of opening and closing contract balances

	Balance sheet classification	October 1, 2018		December 31, 2018		$ change
Contract liabilities	Deferred revenue	$	1,356,502	$	1,375,496	$	18,994

Schedule of anti-dilutive securities not included computation of net loss per share

	2018		2017
Warrants		18,508,527		12,275,455
Stock options		6,177,214		5,304,411
		24,685,741		17,579,866